RxDoctor Payments Data

Katlyn Schmitz, PA

Medical · Saint Paul, MNNPI 1295286425

Payments from drug & device makers

What this record shows

Medtronic accounts for 73.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $945 and has fallen 76.0% since, to $226 in 2025. Among medical clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,360in general payments, 2019–2025

Across 32 payments — averaging $42.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • 180 Medical, Inc.$90
  • Tempus AI, Inc$47
  • Sun Pharmaceutical Industries Inc.$34
  • Merck$29
  • Astellas Pharma US Inc$19
  • plus $137 from 9 others

What the payments were for

  • Travel & lodging$80959%
  • Food & beverage$55141%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,360 in reported general payments places this provider in the 90th percentile of 202 medical providers in Minnesota.

See all medical providers in Minnesota

Medicare billing

Part B allowed, 2024
$50,584
Medicare patients
281
Services billed
1,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron206$196,815
MyrbetriqMirabegron132$133,048
Estradiol188$10,763
Trospium Chloride ErTrospium Chloride32$8,681
Trospium Chloride80$6,564
Methenamine Hippurate34$3,621
Fesoterodine Fumarate ErFesoterodine Fumarate11$3,614
Tolterodine Tartrate ErTolterodine Tartrate14$2,416
YuvafemEstradiol12$1,796
Cephalexin154$1,664
Solifenacin Succinate31$1,216
Oxybutynin Chloride ErOxybutynin Chloride64$1,209
Tamsulosin Hcl67$1,155
Trimethoprim15$912
NitrofurantoinNitrofurantoin Macrocrystal20$813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$19$133,048132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 202 medical providers in Minnesota.

Other medical in Saint Paul

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →